Health Condition 1: D638- Anemia in other chronic diseases classified elsewhere
Conditions
Interventions
Control Intervention1: NIL: nil
Sponsors
Sura. Amarendar
Eligibility
Inclusion criteria
Inclusion criteria: Painful crises (in the past 12 months, there were more than three occurrences) More than two blood transfusions in the last 12 months. The term "painful crisis" refers to an acute painful occurrence that necessitates the use of oral or injectable analgesics and lasts for at least 4 hours when no other reason can be found to account for the symptom Patients under hydroxyurea therapy will be approached to enrol in this study to assess splenic hypofunction
Exclusion criteria
Exclusion criteria: children under the age of 3years and adults over 60years of age concomitant diseases such as neutropenia and thrombocytopenia may have increased the hydroxyureas toxicity Patients who are participating in a particular program or study that could have had an impact on their clinical or haematological state renal dysfunction is indicated by blood creatinine levels that are 1.5 time or more above normal
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anticipate a statistically significant increase in HbF levels in Sickle Cell Anemia patients following Hydroxyurea treatment.Timepoint: 4weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Expect improvement in splenic function, as evidenced by imaging techniques, attributed to the reduction of sickle cell-related complications and improved overall hemoglobin profiles. Envisage a reduction in the frequency and severity of vaso-occlusive crises, leading to improved patient quality of life Timepoint: 1year | — |
Countries
India
Contacts
Public ContactDr Shalini Chandra
Rohilkhand Medical college and Hospital
Outcome results
None listed